Therapeutic Potential of Silodosin for Chronic Prostatitis: Efficacy and Safety Insights: Therapeutic Potential of Silodosin for Chronic Prostatitis

Abdul Basit Niazi; Muhammad Asif; Irfan Ahmad; Wajid Abdullah; Sana Ashraf; Sadia Ghaffar

doi:10.54393/pjhs.v5i07.1883

Authors

Abdul Basit Niazi Department of Urology, Niazi Medical and Dental College, Sargodha, Pakistan
Muhammad Asif Department of Urology, King Edward Medical University, Lahore, Pakistan
Irfan Ahmad Department of Nephrology, Akhtar Saeed Medical and Dental College, Lahore, Pakistan
Wajid Abdullah Department of Nephrology, Niazi Medical and Dental College, Sargodha, Pakistan
Sana Ashraf Department of Pediatrics, Tehsil Headquarter Hospital Raiwind, Lahore, Pakistan
Sadia Ghaffar Department of Obstetrics and Gynecology, Fatima Memorial Medical and Dental College, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i07.1883

Keywords:

Silodosin, Clinical Efficacy, Chronic Prostatitis, Safety

Abstract

Chronic prostatitis is a common urological condition impacting men globally and poses a considerable clinical challenge due to its diverse symptoms and vague causes. The symptoms significantly affect patients' quality of life. Objective: To investigate the efficacy and safety of silodosin in men with chronic prostatitis who have not previously been treated with alpha-blockers for this condition. Methods: A quasi-experimental study was conducted from July 2022 to June 2023 at Niazi Welfare Foundation Teaching Hospital, Sargodha. Eighty-two patients with chronic prostatitis were treated with 4 mg of silodosin once daily and monitored for 12 weeks. Data collection commenced following IRB approval (NM&DC-IRB-43) and informed consent from all participants. Descriptive statistics were used to calculate the mean and standard deviation. Mean differences in NIH-CPSI score were computed through paired t-test at p-value < 0.05, using SPSS version 25.0. Results: Results show noticeable improvement in CP and NIH-CPSI scores following treatment. The change in symptoms of CP and NIH-CPSI score before and after silodosin indication were statistically significant (p < 0.05). Additionally, the treatment was well-tolerated, with minimum adverse events reported. Conclusions: Silodosin, a novel selective inhibitor of the α1A-adrenergic receptor, proved to be effective in treating chronic prostatitis without significant side effects.

References

Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999 Aug; 54(2): 229-33. doi: 10.1016/S0090-4295(99)00205-8. DOI: https://doi.org/10.1016/S0090-4295(99)00205-8

Yebes A, Toribio-Vazquez C, Martinez-Perez S, Quesada-Olarte JM, Rodriguez-Serrano A, Álvarez-Maestro M et al. Prostatitis: a review. Current urology reports. 2023 May; 24(5): 241-51. doi: 10.1007/s11934-023-01150-z. DOI: https://doi.org/10.1007/s11934-023-01150-z

Zhang J, Liang C, Shang X, Li H. Chronic prostatitis/chronic pelvic pain syndrome: a disease or symptom? Current perspectives on diagnosis, treatment, and prognosis. American journal of men's health. 2020 Jan; 14(1): 1557988320903200. doi: 10.1177/1557988320903200. DOI: https://doi.org/10.1177/1557988320903200

Sugimoto M, Hijikata Y, Tohi Y, Kuroda H, Takei M, Matsuki T et al. Low quality of life in men with chronic prostatitis-like symptoms. Prostate Cancer and Prostatic Diseases. 2022 Dec; 25(4): 785-90. doi: 10.1038/s41391-022-00559-w DOI: https://doi.org/10.1038/s41391-022-00559-w

Magistro G and Wagenlehner FM. Chronic prostatitis/chronic pelvic pain syndrome (NIH category III). Evidence‐Based Urology. 2018 Aug: 539-44. doi: 10.1002/9781119129875.ch47. DOI: https://doi.org/10.1002/9781119129875.ch47

Shah AA, Mannan A, Ayub M, Shafi N, Ali A, Raza ZA et al. Questionnaire Survey of Urologists Concerning Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Esculapio Journal of SIMS. 2022 Jun; 18(2): 219-223. doi: doi.org/10.51273/esc22.2518222.

Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome. Drugs & Aging. 2021 Oct; 38: 845-86. doi: 10.1007/s40266-021-00890-2. DOI: https://doi.org/10.1007/s40266-021-00890-2

Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P et al. Comprehensive overview of prostatitis. Biomedicine & Pharmacotherapy. 2017 Oct; 94: 1064-76. doi: 10.1016/j.biopha.2017.08.016. DOI: https://doi.org/10.1016/j.biopha.2017.08.016

Nickel JC. Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate?. Investigative and clinical urology. 2017 May; 58(3): 149-51. doi: 10.4111/icu.2017.58.3.149. DOI: https://doi.org/10.4111/icu.2017.58.3.149

Shoskes DA, Keslar KS, Gotwald P, Berglund R, Vij S. Neuroinflammatory gene expression in chronic prostatitis/chronic pelvic pain syndrome patients: insights into etiology and phenotype biology. Translational andrology and urology. 2021 Aug; 10(8): 3340–3347. doi: 10.21037/tau-21-387. DOI: https://doi.org/10.21037/tau-21-387

Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P et al. Multidisciplinary approach to prostatitis. Archivio Italiano di Urologia e Andrologia. 2018; 90(4): 227-48. doi: 10.4081/aiua.2018.4.227. DOI: https://doi.org/10.4081/aiua.2018.4.227

DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. European Urology Focus. 2019 Jan; 5(1): 2-4. doi: 10.1016/j.euf.2018.08.027. DOI: https://doi.org/10.1016/j.euf.2018.08.027

Franz J, Kieselbach K, Lahmann C, Gratzke C, Miernik A. Chronic primary pelvic pain syndrome in men: differential diagnostic evaluation and treatment. Deutsches Ärzteblatt International. 2023 Jul; 120(29-30): 508-518. doi: 10.3238/arztebl.m2023.0036. DOI: https://doi.org/10.3238/arztebl.m2023.0036

Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews. 2019 Oct; (10). 10.1002/14651858.CD012552.pub2. DOI: https://doi.org/10.1002/14651858.CD012552.pub2

Su ZT, Zenilman JM, Sfanos KS, Herati AS. Management of chronic bacterial prostatitis. Current urology reports. 2020 Jul; 21:1-8. doi: 10.1007/s11934-020-00978-z. DOI: https://doi.org/10.1007/s11934-020-00978-z

Deng W, Du X, Zhou W, Mei X, Tian Y, Chen L et al. Systematic review and meta-analysis: α-adrenergic receptor blockers in chronic prostatitis. Annals of Palliative Medicine. 2021 Sep; 10(9): 9870878-9878. doi: 10.21037/apm-21-2160. DOI: https://doi.org/10.21037/apm-21-2160

Villa L, Capogrosso P, Capitanio U, Martini A, Briganti A, Salonia A et al. Silodosin: an update on efficacy, safety and clinical indications in urology. Advances in Therapy. 2019 Jan; 36: 1-8. doi: 10.1007/s12325-018-0854-2. DOI: https://doi.org/10.1007/s12325-018-0854-2

Krakhotkin DV, Chernylovskyi VA, Bakurov EE, Sperl J. Evaluation of influence of the UPOINT-guided multimodal therapy in men with chronic prostatitis/chronic pelvic pain syndrome on dynamic values NIH-CPSI: a prospective, controlled, comparative study. Therapeutic Advances in Urology. 2019 Jun; 11: 1756287219857271. doi: 10.1177/1756287219857271. DOI: https://doi.org/10.1177/1756287219857271

Gul A, Coban S, Turkoglu AR, Guzelsoy M, Ozturk M, Kankilic NA. Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity. Prostate International. 2020 Dec; 8(4): 152-7. doi: 10.1016/j.prnil.2020.04.002. DOI: https://doi.org/10.1016/j.prnil.2020.04.002

Creta M, Cornu JN, Roehrborn CG, Agrò EF, Montorsi F, Longo N et al. Clinical efficacy of silodosin in patients with severe lower urinary tract symptoms related to benign prostatic obstruction: a pooled analysis of Phase 3 and 4 trials. European Urology Focus. 2021 Mar; 7(2): 440-3. doi: 10.1016/j.euf.2020.01.014. DOI: https://doi.org/10.1016/j.euf.2020.01.014

Jindan L, Xiao W, Liping X. Evolving role of silodosin for the treatment of urological disorders–A narrative review. Drug Design, Development and Therapy. 2023 Dec: 2861-84. doi: 10.2147/DDDT.S373659. DOI: https://doi.org/10.2147/DDDT.S373659

Cho KJ, Lee JZ, Song YS, Choi JB, Kim DK, Kim YT et al. Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: a multicenter, prospective, open-label, single-arm, Phase IV trial. Urology. 2018 Nov; 121: 153-7. doi: 10.1016/j.urology.2018.07.008. DOI: https://doi.org/10.1016/j.urology.2018.07.008